Shannon Stott,
Assistant Professor,
Massachusetts General Hospital & Harvard Medical School
Professor Stott is a Mechanical Engineer that has been working at the interface of technology and medicine. She has an extensive background in microfluidics, optics, and tissue engineering, with a focus on their applications in clinical medicine. As a postdoctoral fellow, she invented the herringbone circulating tumor cell chip (HBCTC-Chip) a device that can successfully capture extremely rare cancer cells circulating in the blood stream cancer patients. Manipulating blood flow for the isolation and separation of biological components has been a hallmark of her work and recent efforts include using nanofluidics to separate extracellular vesicles and nucleic acids from patient samples. The overriding goal of the Stott Laboratory is to use all of these technologies and techniques to improve patient lives through early diagnosis and a greater understanding of how cancer spreads and kills. Dr. Stott has a particular interest in brain tumors and the potential impact of a blood biopsy for adult and pediatric patients.
Exploring the Biophysics of Circulating Tumor Cell Clusters Using Microfluidics
Thursday, 16 March 2017 at 16:00
Add to Calendar ▼2017-03-16 16:00:002017-03-16 17:00:00Europe/LondonExploring the Biophysics of Circulating Tumor Cell Clusters Using MicrofluidicsSELECTBIOenquiries@selectbiosciences.com
Advances in microfluidic technologies, biomaterials and molecular profiling have propelled the rapid growth and interest in achieving a ‘liquid biopsy’ in cancer. As malignant tumors grow, they will aggressively invade surrounding tissue due to rapidly dividing cancer cells that are nourished by an ample blood supply. As these cancer cells are multiplying, individual circulating tumor cells (CTCs) are released into the blood stream at very low numbers (1 in a billion), but are highly desirable due to their molecular cargo. In addition, thousands of tiny particles from the tumor will enter the blood stream, referred to as exosomes, which also contain genetic information about the tumor. Larger aggregates or clusters of tumor cells are thought to break off from the most aggressive cancers. Through a collaborative effort between bioengineers, biologists, and clinicians, my laboratory at Massachusetts General Hospital has developed microfluidic devices to isolate these rare circulating biomarkers from whole blood. Data from these devices will be presented with a focus on our recent effort to characterize the biophysics of clusters of CTCs and what the dynamics of their behavior might mean for understanding their role in metastasis.
Add to Calendar ▼2017-03-16 00:00:002017-03-17 00:00:00Europe/LondonBioMEMS, Microfluidics and Biofabrication: Technologies and ApplicationsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2017-03-16 16:00:002017-03-16 17:00:00Europe/LondonExploring the Biophysics of Circulating Tumor Cell Clusters Using MicrofluidicsSELECTBIOenquiries@selectbiosciences.com
 2_150x75.png)
